Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).

Pardo-Lozano R, Farré M, Yubero-Lahoz S, O'Mathúna B, Torrens M, Mustata C, Pérez-Mañá C, Langohr K, Cuyàs E, Carbó Ml, de la Torre R.

PLoS One. 2012;7(10):e47599. doi: 10.1371/journal.pone.0047599. Epub 2012 Oct 24.

2.

Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT.

Aitchison KJ, Tsapakis EM, Huezo-Diaz P, Kerwin RW, Forsling ML, Wolff K.

J Psychopharmacol. 2012 Mar;26(3):408-18. doi: 10.1177/0269881111434624. Epub 2012 Feb 1.

PMID:
22303032
3.

Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.

Yubero-Lahoz S, Pardo R, Farré M, O'Mahony B, Torrens M, Mustata C, Pérez-Mañá C, Carbó ML, de la Torre R.

Clin Pharmacokinet. 2011 May;50(5):319-29. doi: 10.2165/11584550-000000000-00000.

PMID:
21456632
4.

Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption.

Wolff K, Tsapakis EM, Pariante CM, Kerwin RW, Forsling ML, Aitchison KJ.

J Psychopharmacol. 2012 Mar;26(3):419-28. doi: 10.1177/0269881111415737. Epub 2011 Oct 3.

PMID:
21969106
5.

Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J.

Ther Drug Monit. 2004 Apr;26(2):137-44. Review.

PMID:
15228154
6.

Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.

Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O'Mathúna B, Segura M, de la Torre R.

J Pharmacol Exp Ther. 2007 Dec;323(3):954-62. Epub 2007 Sep 21.

7.

Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions.

Rietjens SJ, Hondebrink L, Westerink RH, Meulenbelt J.

Crit Rev Toxicol. 2012 Nov;42(10):854-76. doi: 10.3109/10408444.2012.725029. Epub 2012 Oct 3. Review.

PMID:
23030234
8.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals.

Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer Zu Schwabedissen HE, Liechti ME.

Pharmacogenet Genomics. 2016 Aug;26(8):397-401. doi: 10.1097/FPC.0000000000000231.

10.

Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Segura M, Farré M, Pichini S, Peiró AM, Roset PN, Ramírez A, Ortuño J, Pacifici R, Zuccaro P, Segura J, de la Torre R.

Clin Pharmacokinet. 2005;44(6):649-60.

PMID:
15910012
11.

Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake.

Yubero-Lahoz S, Kuypers KP, Ramaekers JG, Langohr K, Farré M, de la Torre R.

Psychopharmacology (Berl). 2015 Jun;232(11):1921-9. doi: 10.1007/s00213-014-3827-4. Epub 2014 Dec 20.

PMID:
25524139
12.

Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.

Steuer AE, Schmidhauser C, Tingelhoff EH, Schmid Y, Rickli A, Kraemer T, Liechti ME.

PLoS One. 2016 Mar 11;11(3):e0150955. doi: 10.1371/journal.pone.0150955. eCollection 2016.

13.

Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.

Peiró AM, Farré M, Roset PN, Carbó M, Pujadas M, Torrens M, Camí J, de la Torre R.

Psychopharmacology (Berl). 2013 Feb;225(4):883-93. doi: 10.1007/s00213-012-2894-7. Epub 2012 Nov 10.

PMID:
23142957
14.

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, Camí J.

Br J Clin Pharmacol. 2000 Feb;49(2):104-9.

15.

A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.

Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M.

Am J Psychiatry. 2004 Jul;161(7):1181-9.

PMID:
15229049
16.

The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-O-methyltransferase (COMT) gene.

Schilt T, Koeter MW, de Win MM, Zinkstok JR, van Amelsvoort TA, Schmand B, den Brink Wv.

Eur Neuropsychopharmacol. 2009 Feb;19(2):116-24. doi: 10.1016/j.euroneuro.2008.10.004. Epub 2008 Nov 30.

PMID:
19042106
17.

Gender differences in the subjective effects of MDMA.

Liechti ME, Gamma A, Vollenweider FX.

Psychopharmacology (Berl). 2001 Mar 1;154(2):161-8.

PMID:
11314678
18.

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.

Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, Rostami-Hodjegan A.

J Psychopharmacol. 2006 Nov;20(6):842-9. Epub 2006 May 19.

PMID:
16714321
19.

The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users.

Fagundo AB, Cuyàs E, Verdejo-Garcia A, Khymenets O, Langohr K, Martín-Santos R, Farré M, de la Torre R.

J Psychopharmacol. 2010 Sep;24(9):1381-93. doi: 10.1177/0269881109354926. Epub 2010 Jan 15.

PMID:
20080926
20.

Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Freedman RR, Johanson CE, Tancer ME.

Psychopharmacology (Berl). 2005 Dec;183(2):248-56. Epub 2005 Nov 9.

PMID:
16163516

Supplemental Content

Support Center